Viewing Study NCT04638634


Ignite Creation Date: 2025-12-25 @ 2:31 AM
Ignite Modification Date: 2025-12-26 @ 1:07 AM
Study NCT ID: NCT04638634
Status: TERMINATED
Last Update Posted: 2021-12-10
First Post: 2020-11-19
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Sponsor: CSL Behring
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module